SUPN — SUPERNUS PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About SUPERNUS PHARMACEUTICALS INC (SUPN)
SUPERNUS PHARMACEUTICALS INC (SUPN) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $171M. All data sourced from SEC 13F filings.
Based on recent institutional activity in SUPN
No recent activity recorded.
How many top investors track SUPN
A small number of top investors own this.
SUPN Ownership Composition
How SUPERNUS PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Other78.6%
- Hedge Funds21.4%
Tracked investors reporting SUPN
- Izzy EnglanderMar 31, 2026Millennium ManagementShares3.3MValue$171.4M% Portfolio0.07%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares1.3MValue$68.2M% Portfolio0.09%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares1.5MValue$79M% Portfolio0.01%
Recent activity
- No recent activity.
Frequently asked questions
- How many institutional investors hold SUPN?
- 3 tracked institutional investors disclosed a position in SUPN (SUPERNUS PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of SUPN?
- Izzy Englander, Millennium Management, holds the largest disclosed position in SUPN, valued at $171M.
- Did institutional ownership of SUPN increase or decrease?
- Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited SUPN.
- Where does this SUPN ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.